Several aldo-keto reductases are responsible for the metabolization of oxcarbazepine (AKR1C1, AKR1C2, AKR1C3, and AKR1C4), which have not been found to be expressed in the brain or in gliomas [17]. This evidence concerns the gene AKR1C2 and glioma.